ORIC PHARMACEUTICALS, INC. Net Income
ORIC PHARMACEUTICALS, INC. (ORIC) reported Net Income of -$41.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$41.49M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$35.77M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$30.50M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$32.59M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2023 was -$100.70M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2022 was -$89.12M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2021 was -$78.72M.
- ORIC PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2020 was -$73.70M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$41.49M 10-Q · filed 2026-08-03 | -$77.26M 10-Q · filed 2026-08-03 | -$107.76M derived: sum of 3 quarters · filed 2026-08-03 | -$140.35M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$35.77M 10-Q · filed 2026-05-04 | -$66.27M derived: sum of 2 quarters · filed 2026-05-04 | -$98.86M derived: sum of 3 quarters · filed 2026-05-04 | -$135.21M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$30.50M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$63.09M derived: sum of 2 quarters · filed 2026-04-28 | -$99.45M derived: sum of 3 quarters · filed 2026-08-03 | -$129.47M DEF 14A · filed 2026-04-28 |
| 2025-09-30 | -$32.59M 10-Q · filed 2025-11-13 | -$68.94M derived: sum of 2 quarters · filed 2026-08-03 | -$98.96M 10-Q · filed 2025-11-13 | -$135.27M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$36.35M 10-Q · filed 2026-08-03 | -$66.38M 10-Q · filed 2026-08-03 | -$102.68M derived: sum of 3 quarters · filed 2026-08-03 | -$137.25M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$30.02M 10-Q · filed 2026-05-04 | -$66.33M derived: sum of 2 quarters · filed 2026-05-04 | -$100.89M derived: sum of 3 quarters · filed 2026-05-04 | -$132.86M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$36.31M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$70.87M derived: sum of 2 quarters · filed 2026-04-28 | -$102.84M derived: sum of 3 quarters · filed 2026-04-28 | -$127.85M DEF 14A · filed 2026-04-28 |
| 2024-09-30 | -$34.57M 10-Q · filed 2025-11-13 | -$66.53M derived: sum of 2 quarters · filed 2025-11-13 | -$91.54M 10-Q · filed 2025-11-13 | -$119.87M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$31.96M 10-Q · filed 2025-08-12 | -$56.97M 10-Q · filed 2025-08-12 | -$85.30M derived: sum of 3 quarters · filed 2025-08-12 | -$110.78M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$25.01M 10-Q · filed 2025-05-05 | -$53.34M derived: sum of 2 quarters · filed 2025-05-05 | -$78.82M derived: sum of 3 quarters · filed 2025-05-05 | -$101.76M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$28.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$53.81M derived: sum of 2 quarters · filed 2025-02-18 | -$76.75M derived: sum of 3 quarters · filed 2025-02-18 | -$100.70M 10-K · filed 2025-02-18 |
| 2023-09-30 | -$25.48M 10-Q · filed 2024-11-12 | -$48.42M derived: sum of 2 quarters · filed 2024-11-12 | -$72.37M 10-Q · filed 2024-11-12 | -$93.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$22.94M 10-Q · filed 2024-08-12 | -$46.89M 10-Q · filed 2024-08-12 | -$67.74M derived: sum of 3 quarters · filed 2024-08-12 | -$92.56M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$23.95M 10-Q · filed 2024-05-06 | -$44.79M derived: sum of 2 quarters · filed 2024-05-06 | -$69.62M derived: sum of 3 quarters · filed 2024-05-06 | -$89.91M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$20.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$45.68M derived: sum of 2 quarters · filed 2024-03-11 | -$65.96M derived: sum of 3 quarters · filed 2024-03-11 | -$89.12M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$24.83M 10-Q · filed 2023-11-06 | -$45.12M derived: sum of 2 quarters · filed 2023-11-06 | -$68.28M 10-Q · filed 2023-11-06 | -$91.05M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$20.29M 10-Q · filed 2023-08-10 | -$43.45M 10-Q · filed 2023-08-10 | -$66.22M derived: sum of 3 quarters · filed 2023-08-10 | -$84.64M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$23.16M 10-Q · filed 2023-05-08 | -$45.93M derived: sum of 2 quarters · filed 2023-05-08 | -$64.36M derived: sum of 3 quarters · filed 2023-05-08 | -$85.36M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$22.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$41.20M derived: sum of 2 quarters · filed 2023-03-16 | -$62.21M derived: sum of 3 quarters · filed 2023-03-16 | -$78.72M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$18.43M 10-Q · filed 2022-11-07 | -$39.44M derived: sum of 2 quarters · filed 2022-11-07 | -$55.94M 10-Q · filed 2022-11-07 | -$84.20M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$21.01M 10-Q · filed 2022-08-11 | -$37.52M 10-Q · filed 2022-08-11 | -$65.78M derived: sum of 3 quarters · filed 2022-08-11 | -$91.33M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$16.51M 10-Q · filed 2022-05-09 | -$44.77M derived: sum of 2 quarters · filed 2022-05-09 | -$70.32M derived: sum of 3 quarters · filed 2022-05-09 | -$81.34M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$28.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$53.81M derived: sum of 2 quarters · filed 2022-03-21 | -$64.83M derived: sum of 3 quarters · filed 2022-03-21 | -$73.70M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$25.55M 10-Q · filed 2021-11-08 | -$36.57M derived: sum of 2 quarters · filed 2021-11-08 | -$45.44M 10-Q · filed 2021-11-08 | -$53.80M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-06-30 | -$11.02M 10-Q · filed 2021-08-10 | -$19.90M 10-Q · filed 2021-08-10 | -$28.25M derived: sum of 3 quarters · filed 2022-03-21 | -$34.80M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-03-31 | -$8.87M 10-Q · filed 2021-05-06 | -$17.23M derived: sum of 2 quarters · filed 2022-03-21 | -$23.77M derived: sum of 3 quarters · filed 2022-03-21 | -$29.74M derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | -$8.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$14.90M derived: sum of 2 quarters · filed 2022-03-21 | -$20.87M derived: sum of 3 quarters · filed 2022-03-21 | -$26.88M 10-K · filed 2022-03-21 |
| 2019-09-30 | -$6.55M 10-Q · filed 2020-11-05 | -$12.51M derived: sum of 2 quarters · filed 2020-11-05 | -$18.53M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$5.96M 10-Q · filed 2020-08-05 | -$11.98M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$6.01M 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | -$21.36M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |